PMID: 2499616May 1, 1989Paper

Vasopressin and vasopressin plus nitroglycerin for portal hypertension. Effects on systemic and splanchnic hemodynamics and coronary blood flow

Journal of Hepatology
W G Rector, K F Hossack

Abstract

We measured the coronary, systemic, and splanchnic effects of vasopressin and vasopressin plus nitroglycerin in 8 stable patients with alcoholic cirrhosis. Vasopressin (0.1-0.8 U/min) increased pressure in the hepatic vein, pulmonary artery and pulmonary capillaries. Wedged hepatic (portal) vein pressure was unchanged; the hepatic venous pressure gradient (wedged-free hepatic vein pressure) fell. Insignificant declines occurred in cardiac output, gastroesophageal collateral (azygous) blood flow, hepatic blood flow and coronary sinus (cardiac) blood flow. The addition of nitroglycerin (40-70 micrograms/min) reduced pressure in the hepatic vein, pulmonary artery and pulmonary capillaries, while increasing the hepatic venous pressure gradient. Wedged hepatic vein pressure did not change. Gastroesophageal collateral (azygous) flow increased markedly; cardiac output rose to a lesser degree. Coronary sinus and hepatic blood flow did not change. Nitroglycerin ameliorated the increases in systemic and pulmonary artery pressure produced by vasopressin but also tended to reverse the decline in the hepatic venous pressure gradient and markedly increased gastroesophageal flow. Neither drug significantly affected coronary blood flow.

References

Jul 16, 1979·World Journal of Surgery·W P SkivolockiW G Pace
Dec 1, 1978·Archives of Surgery·S Gelman, E A Ernst
Feb 1, 1975·American Journal of Surgery·K R Sirinek, N R Thomford
Jul 1, 1986·Annals of Internal Medicine·W G Rector
May 1, 1986·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y T TsaiK J Lo
May 1, 1986·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A E GimsonR Williams
Sep 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G Garcia-Tsao, R J Groszmann
Jan 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D VallaD Lebrec
Jan 1, 1986·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A T Blei, J Gottstein
Nov 1, 1974·The American Journal of Physiology·P G SchmidJ W Eckstein
Apr 1, 1971·The American Journal of Cardiology·W GanzH J Swan
Apr 1, 1972·Journal of Applied Physiology·K KitamuraY Wang
Nov 1, 1968·The American Journal of the Medical Sciences·R J CorlissG G Rowe
May 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J Bosch, R J Groszmann
Nov 1, 1982·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R J GroszmannE H Storer
Feb 1, 1980·Annals of Internal Medicine·K J KellyH S Mekhjian
Apr 1, 1980·Annals of Surgery·M F WilsonL B Hinshaw
Oct 1, 1961·Circulation·S SHALDONS SHERLOCK
Jul 21, 1951·Journal of the American Medical Association·I L SLOTNIK, J D TEIGLAND

❮ Previous
Next ❯

Citations

Sep 1, 1994·Journal of Clinical Pharmacology·W G ReissD E Strandness
Mar 1, 1991·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y T TsaiK J Lo
Jun 10, 1998·Anesthesia and Analgesia·P T Overand, J F Teply
Feb 17, 2000·The Annals of Pharmacotherapy·V Rozenfeld, J W Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.